



ATTACHMENT B

REMARKS

In response to the Restriction Requirement dated March 20, 2006, and without addressing the merits of the restriction set forth therein, Applicants elect for examination Group III, Claims 9, 14, 19-26 and 28, drawn to antibodies, antisera, a kit and a pharmaceutical composition comprising an antibody.

In addition, to complete the response, Applicants elect the antibodies that bind to the EF 1093 protein as set forth in SEQ ID NO:13, which is coded by the nucleotide sequence of SEQ ID NO:12.

Further, in response to the notice regarding the sequence listing, Applicants have amended the sequence listing to include the additional sequences referred to by the Examiner in the notice and provide a computer diskette containing the listing in computer readable form. Other appropriate amendments have been made to the specification in order to comply with the sequence listing notice.

STATEMENT

Applicants state in accordance with 37 C.F.R. § 1.821(f) that the content of the enclosed paper sequence listing and computer readable form are the same, and that in accordance with 37 C.F.R. § 1.821(g), the enclosed submission contains no new matter.

Applicant thus submits that the application is now in compliance with the sequence listing requirements, and examination and allowance of this case is earnestly solicited.

END OF REMARKS